Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Study acronym: SURF302
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Interventions modified
    • Eligibility criteria expanded, about 107 words
    • Secondary endpoints: 6 to 7
  2. Study sites: 47 to 48v33
  3. Re-verified, no change to tracked fieldsv32
  4. Study sites: 46 to 47v31
  5. Study sites: 45 to 46v30
Show 28 earlier versionsHide 28 earlier versions
  1. Study sites: 44 to 45v29
  2. Study sites: 42 to 44v28
  3. Study sites: 40 to 42v27
  4. Study sites: 39 to 40v26
  5. Study sites: 38 to 39v25
  6. Study sites: 37 to 38v24
  7. Study sites: 36 to 37v23
  8. Study sites: 35 to 36v22
  9. Study sites: 34 to 35v21
  10. Study sites: 33 to 34v20
  11. Study sites: 31 to 33v19
  12. Study sites: 29 to 31v18
  13. Study sites revised (29)v17
  14. Study sites: 28 to 29v16
  15. Study sites: 27 to 28v15
  16. Study sites: 24 to 27v14
  17. Study sites: 23 to 24v13
  18. Study sites: 16 to 23v12
  19. Study sites: 11 to 16v11
  20. Study sites: 8 to 11v10
  21. Study sites: 5 to 8v9
  22. Study sites: 4 to 5v8
  23. Site contacts updated at 4 of 4 sitesv7
  24. Study sites: 3 to 4v6
  25. Site contacts updated at 1 of 3 sitesv5
  26. Interventions: TYRA-300 (Drug), TYRA-300 (Drug), TYRA-300 Dose TBD (Drug) to TYRA-300 50mg (Drug), TYRA-300 60mg (Drug), TYRA-300 Dose TBD (Drug)
    • Site contacts updated at 2 of 3 sites
    v4
  27. Study sites: 1 to 3
    • Start date changed from estimate of Jun 2025 to Jun 27, 2025
    • Interventions: TYRA-300 50mg (Drug), TYRA-300 60mg (Drug), TYRA-300 Dose TBD (Drug) to TYRA-300 (Drug), TYRA-300 (Drug), TYRA-300 Dose TBD (Drug)
    v3
  28. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: May 2025 to Jun 2025
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Trial Details
NCT Number NCT06995677
Lead Sponsor Tyra Biosciences, Inc
Conditions
(from sponsor)		 Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions
Related terms Non-Muscle Invasive Bladder Neoplasms
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov